A Phase 1, Open-Label, Parallel Group, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986231 in Subjects With Varying Degrees of Renal Function
Phase of Trial: Phase I
Latest Information Update: 19 Nov 2018
At a glance
- Drugs Cimlanod (Primary)
- Indications Acute heart failure
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 05 Nov 2018 Status changed from recruiting to completed.
- 02 Oct 2018 Planned number of patients changed from 42 to 32.
- 02 Oct 2018 Planned End Date changed from 16 Sep 2018 to 6 Oct 2018.